Last updated on September 2020

A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients With Advanced Solid Tumors With KRAS G12C Mutation

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Non-Small Cell Lung Cancer | Colon Cancer | Metastatic Cancer | Solid Tumors
  • Age: Between 18 - 99 Years
  • Gender: Male or Female

Inclusion Criteria:

  • Histologically confirmed diagnosis of a solid tumor malignancy with KRAS G12C mutation
  • Unresectable or metastatic disease
  • Standard treatment is not available or patient declines
  • Adequate organ function

Exclusion Criteria:

  • Active brain metastases
  • History of intestinal disease or major gastric surgery or inability to swallow oral medications
  • Other active cancer

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.